EP300 single nucleotide polymorphism rs20551 correlates with prolonged overall survival in diffuse large B cell lymphoma patients treated with R-CHOP

BACKGROUND: Rituximab combined with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) is used as standard frontline regimen for diffuse large B-cell lymphoma (DLBCL). The landscape of somatic mutations in DLBCL revealed that inactivation of EP300 plays an important role in lymphomagen...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jiao, Ding, Ning, Wang, Xiaogan, Mi, Lan, Ping, Lingyan, Jin, Xuan, Liu, Yalu, Ying, Zhitao, Xie, Yan, Liu, Weiping, Song, Yuqin, Zhu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5513029/
https://www.ncbi.nlm.nih.gov/pubmed/28725161
http://dx.doi.org/10.1186/s12935-017-0439-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5513029/
https://www.ncbi.nlm.nih.gov/pubmed/28725161
http://dx.doi.org/10.1186/s12935-017-0439-1

Ejemplares similares